COMMUNIQUÉS West-GlobeNewswire

PCI Biotech second half 2023 interim results
14/02/2024
Oslo (Norway), 14 February 2024 – PCI Biotech (OSE: PCIB), today announces its interim second half 2023 results. Please find enclosed the interim report and presentation. Highlights review Operations The use of fima NAc [...]
Ultimovacs ASA Reports Fourth Quarter 2023 Financial Results and Provides General Business Update
14/02/2024
Readout of topline result expected in March 2024 from UV1 randomized Phase II trial INITIUM in Ultimovacs’ lead indication, advanced malignant melanoma Topline result will report primary endpoint of progression-free [...]
Ibogaine By David Dardashti Encourages Couples to Get Clean Together This Valentine's Day
14/02/2024
Research on the bond of couples who get clean together MIAMI, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Ibogaine By David Dardashti, a leading addiction recovery clinic, is proud to present their research on couples who get [...]
NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
14/02/2024
NAARDEN, the Netherlands and MIAMI, Feb. 13, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS ; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, [...]
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
14/02/2024
IRVINE, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that the Company’s Compensation Committee granted 42,500 restricted stock units (RSUs) and stock [...]
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024
13/02/2024
FDA approved LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL Additional USAFA funding commitment from the U.S. Air Force Academy, intended to advance the ATI-1701 program toward an IND submission to the [...]
Globus Medical Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call
13/02/2024
AUDUBON, Pa., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Globus Medical , Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full year ended December 31 [...]
Metagenomi Announces Closing of Initial Public Offering
13/02/2024
EMERYVILLE, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive [...]
Natural Alternatives International, Inc. Announces 2024 Q2 and YTD Results
13/02/2024
CARLSBAD, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today [...]
Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024
13/02/2024
ALACHUA, Fla. and TAMPA, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that [...]
Progyny, Inc. Announces Details for Its Fourth Quarter and Full Year 2023 Results Report
13/02/2024
NEW YORK, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women’s health benefits solution, will report its financial results for the quarterly period and [...]
Larimar Therapeutics Announces Proposed Underwritten Public Offering
13/02/2024
BALA CYNWYD, Pa., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today [...]
Voting Rights and Shares Capital of the Company
13/02/2024
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Feb. 13, 2024 (GLOBE NEWSWIRE [...]
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
13/02/2024
Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 13 févr. 2024 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / Nasdaq Euronext [...]
Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA
13/02/2024
Approval based on Phase III NAPOLI 3 clinical trial in which Onivyde ® regimen (NALIRIFOX) demonstrated statistically significant superiority and clinically meaningful improvements in overall survival and progression- [...]
Ipsen reçoit l’approbation de la FDA pour le schéma thérapeutique incluant Onivyde®, un potentiel nouveau traitement de référence en première ligne dans l'adénocarcinome du pancréas métastatique
13/02/2024
Approbation basée sur l'essai clinique de Phase III NAPOLI 3 dans lequel le schéma thérapeutique d'Onivyde ® (NALIRIFOX) a démontré une supériorité statistiquement significative ainsi que des améliorations cliniquement [...]
Codexis Secures $40 Million in Strategic Financing Deal with Innovatus Capital Partners to Further Strengthen Cash Position Ahead of Key Milestones
13/02/2024
Term loan agreement enables Company to accelerate development and enhance commercialization of ECO Synthesis™ manufacturing platform for RNAi therapeutics Financing bolsters cash position and provides additional [...]
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024
13/02/2024
ROCKVILLE, Md., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system [...]
Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP
13/02/2024
Transplant of HIP-modified pancreatic islet cells provided lasting glucose control in a fully immunocompetent non-human primate (NHP), enabling the achievement of exogenous insulin independence without immunosuppression [...]

Pages